Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes

Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes

Introduction No direct comparisons have evaluated glucagon-like peptide-1 receptor agonists (GLP-1 RAs) versus metformin as first-line antidiabetic therapy for preventing dementia in patients with type 2 diabetes mellitus (T2DM). This study aimed to assess the comparative effectiveness of GLP-1 RAs...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoling Wang, Mengrong Miao, Yitian Yang, Jiaqiang Zhang, Mingyang Sun, Wan-Ming Chen, Zhongyuan Lu, Shuang Lv, Szu Yuan Wu
Format: Article
Language:English
Published: BMJ Publishing Group 2025-07-01
Series:BMJ Open Diabetes Research & Care
Online Access:https://drc.bmj.com/content/13/4/e004902.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://drc.bmj.com/content/13/4/e004902.full

Similar Items